Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

Kelley, RK
Verslype, C
Cohn, AL
Yang, T-S
Su, W-C
Burris, H
Braiteh, F
Vogelzang, N
Spira, A
Foster, P
Lee, Y
Van Cutsem, E

March 2017

BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and...

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.

Kelley, RK
Verslype, C
Cohn, AL
Yang, T-S
Su, W-C
Burris, H
Braiteh, F
Vogelzang, N
Spira, A
Foster, P
Lee, Y
Van Cutsem, E

March 2017

BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and...

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

Daud, Adil
Kluger, Harriet M
Kurzrock, Razelle
Schimmoller, Frauke
Weitzman, Aaron L
Samuel, Thomas A
Moussa, Ali H
Gordon, Michael S
Shapiro, Geoffrey I

February 2017

BackgroundA phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioav...

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Schöffski, Patrick
Gordon, Michael
Smith, David C
Kurzrock, Razelle
Daud, Adil
Vogelzang, Nicholas J
Lee, Yihua
Scheffold, Christian
Shapiro, Geoffrey I

November 2017

Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth fa...

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Schöffski, Patrick
Gordon, Michael
Smith, David C
Kurzrock, Razelle
Daud, Adil
Vogelzang, Nicholas J
Lee, Yihua
Scheffold, Christian
Shapiro, Geoffrey I

November 2017

Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth fa...

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

Tolaney, Sara M
Nechushtan, Hovav
Ron, Ilan-Gil
Schöffski, Patrick
Awada, Ahmad
Yasenchak, Chris A
Laird, A Douglas
O'Keeffe, Bridget
Shapiro, Geoffrey I
Winer, Eric P

January 2016

Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEG...

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

Kelley, RK
Verslype, Chris
Cohn, AL
Yang, T-S
Su, W-C
Burris, H
Braiteh, F
Vogelzang, N
Spira, A
Foster, P
Lee, Y
Van Cutsem, Eric

January 2017

Background: Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, a...

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

Tolaney, Sara S.M.
Winer, Eric E.P.
Nechushtan, Hovav
Ron, Ilan Gil
Schöffski, Patrick
Awada, Ahmad
Yasenchak, Christopher C.A.
Laird, Alexander Douglas
O’Keeffe, Bridget
Shapiro, Geoffrey G.I.

November 2016

Purpose: Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against...

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

Tolaney, Sara M
Nechushtan, Hovav
Ron, Ilan-Gil
Schöffski, Patrick
Awada, Ahmad
Yasenchak, Chris A
Laird, A Douglas
O'Keeffe, Bridget
Shapiro, Geoffrey I
Winer, Eric P

January 2016

Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEG...

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Smith, Matthew R.
Sweeney, Christopher J.
Corn, Paul G.
Rathkopf, Dana E.
Smith, David C.
Hussain, Maha
George, Daniel J.
Higano, Celestia S.
Harzstark, Andrea L.
Sartor, A. Oliver
Vogelzang, Nicholas J.
Gordon, Michael S.
de Bono, Johann S.
Haas, Naomi B.
Logothetis, Christopher J.
Elfiky, Aymen
Scheffold, Christian
Laird, A. Douglas
Schimmoller, Frauke
Basch, Ethan M.
Scher, Howard I.

January 2014

Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2...

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Smith, Matthew R.
Sweeney, Christopher J.
Corn, Paul G.
Rathkopf, Dana E.
Smith, David C.
Hussain, Maha
George, Daniel J.
Higano, Celestia S.
Harzstark, Andrea L.
Sartor, A. Oliver
Vogelzang, Nicholas J.
Gordon, Michael S.
de Bono, Johann S.
Haas, Naomi B.
Logothetis, Christopher J.
Elfiky, Aymen
Scheffold, Christian
Laird, A. Douglas
Schimmoller, Frauke
Basch, Ethan M.
Scher, Howard I.

January 2014

Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2...

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, Ignace
Smith, David C
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G
Weitzman, Ron
Buckanovich, Ronald J

September 2017

Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor recepto...

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, Ignace
Smith, David C
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G
Weitzman, Ron
Buckanovich, Ronald J

September 2017

Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor recepto...

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'

Schoffski, Patrick
Mir, Olivier
Kasper, Bernd
Papai, Zsuzsanna
Blay, Jean-Yves
Italiano, Antoine
Benson, Charlotte
Kopeckova, Katerina
Ali, Nasim
Dileo, Palma
LeCesne, Axel
Menge, Franka
Cousin, Sophie
Wardelmann, Eva
Wozniak, Agnieszka
Marreaud, Sandrine
Litiere, Saskia
Zaffaroni, Facundo
Nzokirantevye, Axelle
Bempt, Isabelle Vanden
Gelderblom, Hans

July 2020

BACKGROUND: Gastrointestinal stromal tumour (GIST) is commonly treated with tyrosine kinase inhibito...

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'

Schoffski, P.
Mir, O.
Kasper, B.
Papai, Z.
Blay, J.Y.
Italiano, A.
Benson, C.
Kopeckova, K.
Ali, N.
Dileo, P.
LeCesne, A.
Menge, F.
Cousin, S.
Wardelmann, E.
Wozniak, A.
Marreaud, S.
Litiere, S.
Zaffaroni, F.
Nzokirantevye, A.
Bempt, I.V.
Gelderblom, H.

July 2020

Background: Gastrointestinal stromal tumour (GIST) is commonly treated with tyrosine kinase inhibito...

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

Kelley, RK
Verslype, C
Cohn, AL
Yang, T-S
Su, W-C
Burris, H
Braiteh, F
Vogelzang, N
Spira, A
Foster, P
Lee, Y
Van Cutsem, E

March 2017

BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and...

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.

Kelley, RK
Verslype, C
Cohn, AL
Yang, T-S
Su, W-C
Burris, H
Braiteh, F
Vogelzang, N
Spira, A
Foster, P
Lee, Y
Van Cutsem, E

March 2017

BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and...

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

Daud, Adil
Kluger, Harriet M
Kurzrock, Razelle
Schimmoller, Frauke
Weitzman, Aaron L
Samuel, Thomas A
Moussa, Ali H
Gordon, Michael S
Shapiro, Geoffrey I

February 2017

BackgroundA phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioav...

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Schöffski, Patrick
Gordon, Michael
Smith, David C
Kurzrock, Razelle
Daud, Adil
Vogelzang, Nicholas J
Lee, Yihua
Scheffold, Christian
Shapiro, Geoffrey I

November 2017

Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth fa...

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Schöffski, Patrick
Gordon, Michael
Smith, David C
Kurzrock, Razelle
Daud, Adil
Vogelzang, Nicholas J
Lee, Yihua
Scheffold, Christian
Shapiro, Geoffrey I

November 2017

Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth fa...

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

Tolaney, Sara M
Nechushtan, Hovav
Ron, Ilan-Gil
Schöffski, Patrick
Awada, Ahmad
Yasenchak, Chris A
Laird, A Douglas
O'Keeffe, Bridget
Shapiro, Geoffrey I
Winer, Eric P

January 2016

Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEG...

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

Kelley, RK
Verslype, Chris
Cohn, AL
Yang, T-S
Su, W-C
Burris, H
Braiteh, F
Vogelzang, N
Spira, A
Foster, P
Lee, Y
Van Cutsem, Eric

January 2017

Background: Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, a...

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

Tolaney, Sara S.M.
Winer, Eric E.P.
Nechushtan, Hovav
Ron, Ilan Gil
Schöffski, Patrick
Awada, Ahmad
Yasenchak, Christopher C.A.
Laird, Alexander Douglas
O’Keeffe, Bridget
Shapiro, Geoffrey G.I.

November 2016

Purpose: Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against...

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

Tolaney, Sara M
Nechushtan, Hovav
Ron, Ilan-Gil
Schöffski, Patrick
Awada, Ahmad
Yasenchak, Chris A
Laird, A Douglas
O'Keeffe, Bridget
Shapiro, Geoffrey I
Winer, Eric P

January 2016

Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEG...

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Smith, Matthew R.
Sweeney, Christopher J.
Corn, Paul G.
Rathkopf, Dana E.
Smith, David C.
Hussain, Maha
George, Daniel J.
Higano, Celestia S.
Harzstark, Andrea L.
Sartor, A. Oliver
Vogelzang, Nicholas J.
Gordon, Michael S.
de Bono, Johann S.
Haas, Naomi B.
Logothetis, Christopher J.
Elfiky, Aymen
Scheffold, Christian
Laird, A. Douglas
Schimmoller, Frauke
Basch, Ethan M.
Scher, Howard I.

January 2014

Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2...

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Smith, Matthew R.
Sweeney, Christopher J.
Corn, Paul G.
Rathkopf, Dana E.
Smith, David C.
Hussain, Maha
George, Daniel J.
Higano, Celestia S.
Harzstark, Andrea L.
Sartor, A. Oliver
Vogelzang, Nicholas J.
Gordon, Michael S.
de Bono, Johann S.
Haas, Naomi B.
Logothetis, Christopher J.
Elfiky, Aymen
Scheffold, Christian
Laird, A. Douglas
Schimmoller, Frauke
Basch, Ethan M.
Scher, Howard I.

January 2014

Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2...

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, Ignace
Smith, David C
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G
Weitzman, Ron
Buckanovich, Ronald J

September 2017

Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor recepto...

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Vergote, Ignace
Smith, David C
Berger, Raanan
Kurzrock, Razelle
Vogelzang, Nicholas J
Sella, Avishay
Wheler, Jennifer
Lee, Yihua
Foster, Paul G
Weitzman, Ron
Buckanovich, Ronald J

September 2017

Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor recepto...

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'

Schoffski, Patrick
Mir, Olivier
Kasper, Bernd
Papai, Zsuzsanna
Blay, Jean-Yves
Italiano, Antoine
Benson, Charlotte
Kopeckova, Katerina
Ali, Nasim
Dileo, Palma
LeCesne, Axel
Menge, Franka
Cousin, Sophie
Wardelmann, Eva
Wozniak, Agnieszka
Marreaud, Sandrine
Litiere, Saskia
Zaffaroni, Facundo
Nzokirantevye, Axelle
Bempt, Isabelle Vanden
Gelderblom, Hans

July 2020

BACKGROUND: Gastrointestinal stromal tumour (GIST) is commonly treated with tyrosine kinase inhibito...

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'

Schoffski, P.
Mir, O.
Kasper, B.
Papai, Z.
Blay, J.Y.
Italiano, A.
Benson, C.
Kopeckova, K.
Ali, N.
Dileo, P.
LeCesne, A.
Menge, F.
Cousin, S.
Wardelmann, E.
Wozniak, A.
Marreaud, S.
Litiere, S.
Zaffaroni, F.
Nzokirantevye, A.
Bempt, I.V.
Gelderblom, H.

July 2020

Background: Gastrointestinal stromal tumour (GIST) is commonly treated with tyrosine kinase inhibito...

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

Kelley, RK
Verslype, C
Cohn, AL
Yang, T-S
Su, W-C
Burris, H
Braiteh, F
Vogelzang, N
Spira, A
Foster, P
Lee, Y
Van Cutsem, E

March 2017

BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and...

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.

Kelley, RK
Verslype, C
Cohn, AL
Yang, T-S
Su, W-C
Burris, H
Braiteh, F
Vogelzang, N
Spira, A
Foster, P
Lee, Y
Van Cutsem, E

March 2017

BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and...

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

Daud, Adil
Kluger, Harriet M
Kurzrock, Razelle
Schimmoller, Frauke
Weitzman, Aaron L
Samuel, Thomas A
Moussa, Ali H
Gordon, Michael S
Shapiro, Geoffrey I

February 2017

BackgroundA phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioav...

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

Abstract

Extracted data

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

Abstract

Extracted data

Related items

Related items